Abstract: There are provided a therapeutic preparation for anxiety neurosis or depression which comprises a MC4 receptor antagonist as an effective ingredient; and a piperazine derivative represented by Formula [1]: [wherein Ar1 is a phenyl group, a substituted phenyl group, a naphthyl group or a substituted naphthyl group; Ar2 is a naphthyl group, a substituted naphthyl group, a quinolyl group, a group represented by the formula: (wherein R4 is a hydrogen atom or a halogen atom; and X—Y is CH—NH, CH—O, CH—S or N—O) or a group represented by the formula: (wherein R5 is a hydrogen atom, a hydroxyl group or a C1-10 alkoxy group); R1 is a hydrogen atom, a C1-10 alkyl group, a C3-8 cycloalkyl group, a C3-10 alkenyl group, a phenyl group, a 1-cyanoethyl group, a pyrimidin-2-yl group or an amidyl group; R2 and R3 are the same or different, and are each a hydrogen atom or a C1-10 alkyl group; A-B is N—CH2, CH—CH2, C(OH)—CH2 or C?CH; T1 is a single bond, —N(R6)— (wherein R6 is a hydrogen atom or a C1-10 alkyl group

Abstract: A PLL (Phase-Locked Loop)-controlled oscillator has a temperature-compensated crystal oscillator having a quartz crystal unit, an oscillating circuit connected to the crystal unit, and a temperature compensating mechanism for generating a temperature compensating voltage for compensating for frequency vs. temperature characteristics of the crystal unit, and a voltage-controlled oscillator having an LC oscillating circuit, for being controlled by a PLL using the temperature-compensated crystal oscillator as a reference signal source. The temperature-compensated crystal oscillator has circuit components except for the crystal unit, the circuit components and the voltage-controlled oscillator being integrated in a one-chip IC. The one-chip IC and the crystal unit are integrally combined with each other in the PLL-controlled oscillator.

Abstract: An inhibitor for 20-hydroxyeicosatetraenoic acid production which comprises as the active ingredient a specific hydroxyformamidine derivative or a pharmacologically acceptable salt thereof. It is useful especially as a remedy for kidney diseases, cerebrovascular diseases, or circulatory diseases. The novel hydroxyformamidine derivative or pharmacologically acceptable salt thereof is also provided.

Abstract: A PLL (Phase-Locked Loop)-controlled oscillator has a temperature-compensated crystal oscillator having a quartz crystal unit, an oscillating circuit connected to the crystal unit, and a temperature compensating mechanism for generating a temperature compensating voltage for compensating for frequency vs. temperature characteristics of the crystal unit, and a voltage-controlled oscillator having an LC oscillating circuit, for being controlled by a PLL using the temperature-compensated crystal oscillator as a reference signal source. The temperature-compensated crystal oscillator has circuit components except for the crystal unit, the circuit components and the voltage-controlled oscillator being integrated in a one-chip IC. The one-chip IC and the crystal unit are integrally combined with each other in the PLL-controlled oscillator.

Abstract: A hydroxyformamidine compound represented by the following formula or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to an inhibitor for production of 20-hydroxyeicosatetraenoic acid, comprising, as an effective ingredient, specific hydroxyformamidine derivatives or pharmaceutically-acceptable salts thereof. The inhibitors according to the present invention are useful as therapeutic agents for kidney diseases, cerebrovascular diseases, or circulatory diseases.

Abstract: Pharmaceutical agents for inhibiting the production of 20-HETE which participates in constriction or dilation of microvessels in major organs such as the kidneys and the cerebral blood vessels, or participates in causing cell proliferation are provided.

Abstract: Pharmaceutical agents for inhibiting the production of 20-HETE which participates in constriction or dilation of microvessels in major organs such as the kidneys and the cerebral blood vessels, or participates in causing cell proliferation are provided.

Abstract: There are provided a therapeutic preparation for anxiety neurosis or depression which comprises a MC4 receptor antagonist as an effective ingredient; and a piperazine derivative represented by Formula [1]: 1

Abstract: A method and apparatus for inspecting chips formed as a fine pattern on a surface of an object to be inspected, in which one visual field of an optical observation system is divided into a plurality of areas. A plurality of predetermined good chips are arranged sequentially to each area. Image data of the predetermined good chips are stored at each specific position of the area. In addition, one visual field of the optical observation system is divided into a plurality of areas. When a plurality of good chips are observed in one visual field, coordinates of each good chip are memorized. When good chips in the visual field during learning are recognized, image of the area is obtained as a learned image. Even if the plurality of chips in one visual field of the optical observation system are not entirely nondefective, it can inspect effectively the chips. Further, a problem caused by distortion (distortion aberration) in the optical observation system can be solved.

Abstract: In a game machine which comprises a roulette part for rotating an indicating mark along an outside of a play field, the indicating mark is stopped in accordance with a signal from a stop switch. If the indicating mark is stopped in a center position of a prize area which is indicated with a chance gage, a payment of medals as a reward is allowed. If the indicating mark is stopped in a position which is included in the prize area but don't coincide with the center position, a process of a lottery with a random number is carried out and a gage volume of a level gage is changed in the basis of the random number. An additional chance of a payment of medals is given corresponding to a position in which the indicating mark is stopped.

Abstract: An erythromycin A derivative represented by Formula wherein R1 is a group represented by the formula: a group represented by the formula: (c) pyridylacetyl, (d) cycloalkylmethyl or (e) 1,2 bis-(ethoxycarbonyl)vinyl, R2 is the same group as defined for R1, hydrogen, alkyl, alkanoyl, alkoxycarbonyl, R1 and R2 together may form ═CH—R14, or R1 and R2 together with the nitrogen atom to which they are attached may form: R3 is hydrogen, alkyl or cinnamyl, R4 is hydrogen, acetyl, ethylsuccinyl or nicotinoyl, A is —OC(═O)—R17, —OC(═O)—CH2—R17, —OC(═O)—NH—R17, —O—R17 or —OC(═O)—O—R17, and R5 and R6 are each hydrogen or alkyl.

Abstract: An erythromycin A derivative represented by the formula: wherein n is an integer of from 1 to 8, R1 is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R2 is a pyridylmethyl group, a quinolylmethyl group, a pyridylsulfonyl group or quinolylsulfonyl group, R3 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or a cinnamyl group, R4 is a cladinosyloxy group or a group represented by the formula: wherein m is 0 or 1, R5 is a pyridyl group, a quinolyl group, a phenyl group, a phenyl group substituted with one, two or three members selected from alkyl groups having 1 to 6 carbon atoms, a nitro group, alkoxy groups having 1 to 3 carbon atoms and halogen atoms, or a pyridyl or quinolyl group substituted with one or two members selected from alkyl groups having 1 to 6 carbon atoms, a nitro group, alkoxy groups having 1 to 3 carbon atoms and halogen atoms; or a pharmaceutically acceptable salt thereof.

Abstract: An erythromycin A derivative represented by Formula (I): ##STR1## (wherein n is an integer of 2 to 4, R.sup.1 is a pyridylmethyl group, a furylmethyl group, a thienylmethyl group, a quinolylmethyl group or a benzyl group having 1 to 3 substitutents selected from the group consisting of an alkyl group having 1 to 5 carbon atoms, a nitro group, an alkoxy group having 1 to 5 carbon atoms, an amino group and an amino group substituted by 1 or 2 alkyl groups having 1 to 5 carbon atoms, R.sup.2 is the same group as defined for R.sup.1, a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an acetyl group or a pyridylacetyl group, and R.sup.3 is an alkyl group having 1 to 5 carbon atoms or a cinnamyl group) or a pharmaceutically acceptable salt thereof has a strong antibacterial activity against not only known erythromycin-sensitive bacteria but also erythromycin-resistant bacteria and Haemophilus influenzae.

Abstract: An erythromycin A derivative represented by Formula (I): ##STR1## wherein R is a pyridyl group, a quinolyl group, a nitrophenyl group or a methoxyphenyl group, or a pharmaceutically acceptable salt thereof has a strong antibacterial activity not only against erythromycin-sensitive bacteria but also against certain erythromycin-resistant bacteria and Haemophilus influenzae.

Abstract: The positive potential side output of a voltage source (1) is connected to the positive potential side of a first circuit (10) through a terminal (6); the ground (negative potential) side output of voltage source (1) is connected through a terminal (8) to the ground (negative potential) side of first circuit (10). Also, the positive potential side output of voltage source (1) is lowered by a prescribed voltage .DELTA. V by a Schottky barrier diode (2) and is connected to the positive potential side of second circuit (11) through a terminal (7); the ground (negative potential) side output of voltage source (1) is raised by a prescribed voltage .DELTA. V by a Schottky barrier diode (4) and is connected to the ground (negative potential) side of second circuit (11) through a terminal (9). A power supply voltage supplying circuit can thereby be provided wherein latch-up is avoided while still keeping current consumption and electromagnetic interference (EMI) low.

Abstract: A radio telephone apparatus power-supplied with a battery comprises a power supply control .[.means.]. for controlling the battery so as to terminate power supply if the apparatus is not operated for a predetermined time period. The apparatus further comprises .[.means.]. .Iadd.an alerting device .Iaddend.for informing .[.at least.]. a user of the termination of power supply prior to the power being turned off.